Nanoparticles restore lysosomal acidification defects: Implications for Parkinson and other lysosomal-related diseases.
about
Lysosomal Re-acidification Prevents Lysosphingolipid-Induced Lysosomal Impairment and Cellular ToxicityModulation of mTOR signaling as a strategy for the treatment of Pompe disease.Misrouting of v-ATPase subunit V0a1 dysregulates lysosomal acidification in a neurodegenerative lysosomal storage disease model.Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.Targeting α-synuclein: Therapeutic options.Therapeutic potential of autophagy-enhancing agents in Parkinson's disease.Disorders of lysosomal acidification-The emerging role of v-ATPase in aging and neurodegenerative disease.Systems-level thinking for nanoparticle-mediated therapeutic delivery to neurological diseases.In utero delivery of rAAV2/9 induces neuronal expression of the transgene in the brain: towards new models of Parkinson's disease.N370S-GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease.Mini-review on initiatives to interfere with the propagation and clearance of alpha-synuclein in Parkinson's disease.The physiological determinants of drug-induced lysosomal stress resistance.Central neurotoxicity induced by the instillation of ZnO and TiO2 nanoparticles through the taste nerve pathway.Effects of mild running on substantia nigra during early neurodegeneration.Dysfunction of autophagy and endosomal-lysosomal pathways: Roles in pathogenesis of Down syndrome and Alzheimer's Disease.Lysosomal Acidification in Cultured Astrocytes Using Nanoparticles.From the Cover: Potentiation of Drug-Induced Phospholipidosis In Vitro through PEGlyated Graphene Oxide as the Nanocarrier.[Autophagy and brain: the case of neurodegenerative diseases].Analysis of Lysosomal pH by Flow Cytometry Using FITC-Dextran Loaded Cells.
P2860
Q28555118-F075D3CC-61C0-4220-AFD3-A81EBCD708F1Q37672756-666B97FA-641C-4476-9EB5-CC8A66B80DB6Q37691503-8763FFBC-1158-4E7F-A804-63630F1497E8Q38684097-EC0A4895-E011-437A-AC77-C21141C56D32Q38754587-79C3ABD7-87FF-4033-BF81-EF21955DDC78Q38765856-CF1CA494-7861-4A92-97A9-73FAE4F34376Q38838536-AF1D4F7A-FA2F-4EFA-A100-18A77704EB7BQ38937398-D01AABE1-E63A-418F-990F-065E09F4A2BAQ40065184-A403CA3F-8312-46CA-A645-FCC9463254CCQ46325430-D7BA02C5-12B6-40E9-B4B1-780CB045DEFEQ47123483-543A107E-B447-47F6-B951-66CA05C60C2CQ47167970-F9335E3C-111B-48E6-9116-9CAB06082878Q47859436-4F62D8E0-2D0B-4ED0-8368-30F47E27748DQ48363359-031C8628-041F-436B-A10D-47AECC1C28F6Q49497621-98BDC4C5-AD90-473E-B2DD-DC24DBAF7C33Q50863292-C9E3D13B-AC19-4E68-BB80-EA31DD7471D0Q51237623-5A9A130B-8D42-4E96-A128-659A5B74EA9DQ51831274-DFF38D88-3310-4CBD-BE64-78D17AF4CB87Q52774038-DAE2643A-55F1-402D-974C-6A7DB062AE16
P2860
Nanoparticles restore lysosomal acidification defects: Implications for Parkinson and other lysosomal-related diseases.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Nanoparticles restore lysosoma ...... er lysosomal-related diseases.
@ast
Nanoparticles restore lysosoma ...... er lysosomal-related diseases.
@en
type
label
Nanoparticles restore lysosoma ...... er lysosomal-related diseases.
@ast
Nanoparticles restore lysosoma ...... er lysosomal-related diseases.
@en
prefLabel
Nanoparticles restore lysosoma ...... er lysosomal-related diseases.
@ast
Nanoparticles restore lysosoma ...... er lysosomal-related diseases.
@en
P2093
P2860
P50
P1433
P1476
Nanoparticles restore lysosoma ...... er lysosomal-related diseases.
@en
P2093
Emilie Genin
Jonathan Daniel
Mireille Blanchard-Desce
P2860
P304
P356
10.1080/15548627.2015.1136769
P577
2016-01-13T00:00:00Z